Entellus Medical Company Profile (NASDAQ:ENTL)

About Entellus Medical (NASDAQ:ENTL)

Entellus Medical logoEntellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENTL
  • CUSIP: N/A
  • Web: www.entellusmedical.com
Capitalization:
  • Market Cap: $427.5 million
  • Outstanding Shares: 25,371,000
Average Prices:
  • 50 Day Moving Avg: $17.37
  • 200 Day Moving Avg: $17.37
  • 52 Week Range: $12.31 - $22.57
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.36
  • P/E Growth: -0.32
Sales & Book Value:
  • Annual Revenue: $80.8 million
  • Price / Sales: 5.29
  • Book Value: $3.16 per share
  • Price / Book: 5.33
Profitability:
  • EBIDTA: ($26,990,000.00)
  • Net Margins: -41.11%
  • Return on Equity: -60.34%
  • Return on Assets: -36.76%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 3.87%
  • Quick Ratio: 3.53%
Misc:
  • Average Volume: 133,029 shs.
  • Beta: 0.04
  • Short Ratio: 12.52
 

Frequently Asked Questions for Entellus Medical (NASDAQ:ENTL)

What is Entellus Medical's stock symbol?

Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."

How were Entellus Medical's earnings last quarter?

Entellus Medical, Inc. (NASDAQ:ENTL) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.03. The firm earned $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business's revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.27) EPS. View Entellus Medical's Earnings History.

When will Entellus Medical make its next earnings announcement?

Entellus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Entellus Medical.

Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?

7 equities research analysts have issued 12 month price objectives for Entellus Medical's shares. Their predictions range from $16.00 to $26.00. On average, they expect Entellus Medical's share price to reach $21.83 in the next year. View Analyst Ratings for Entellus Medical.

What are analysts saying about Entellus Medical stock?

Here are some recent quotes from research analysts about Entellus Medical stock:

  • 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (8/1/2017)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)

Who are some of Entellus Medical's key competitors?

Who are Entellus Medical's key executives?

Entellus Medical's management team includes the folowing people:

  • Robert S. White, President, Chief Executive Officer, Director
  • Brent A. Moen, Chief Financial Officer, Corporate Secretary
  • Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel
  • Stephen R. Paidosh, Vice President, Operations
  • Thomas D. Williamson, Vice President - Sales
  • Kevin L. Mensink, Vice President of Marketing
  • Martha J. Christian, Vice President, Reimbursement
  • Timothy B. Petrick, Vice President, Research and Development
  • Brian E. Farley, Non-Executive Chairman of the Board
  • James C. Momtazee, Director

When did Entellus Medical IPO?

(ENTL) raised $70 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Entellus Medical stock?

Entellus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include SV Health Investors LLC (13.49%), DISCOVERY GROUP I, LLC (8.50%), KKR FUND HOLDINGS L.P. (5.50%), Frontier Capital Management Co. LLC (3.95%), First Light Asset Management LLC (2.02%) and Vanguard Group Inc. (2.21%). Company insiders that own Entellus Medical stock include Brent Moen, Brian E Farley, James D Surek, Joshua J Baltzell, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano, Robert S White, Stephen R Paidosh and Timothy B Petrick. View Institutional Ownership Trends for Entellus Medical.

Who sold Entellus Medical stock? Who is selling Entellus Medical stock?

Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Federated Investors Inc. PA, Royce & Associates LP, Quinn Opportunity Partners LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN and New York State Common Retirement Fund. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, Karen E Peterson, Life Sciences Fu International, Margaret A Boiano and Stephen R Paidosh. View Insider Buying and Selling for Entellus Medical.

Who bought Entellus Medical stock? Who is buying Entellus Medical stock?

Entellus Medical's stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Tekla Capital Management LLC, Nicholas Company Inc., First Manhattan Co., Archon Capital Management LLC, First Light Asset Management LLC, Paulson & CO. Inc. and Cypress Capital Management LLC WY. Company insiders that have bought Entellus Medical stock in the last two years include Brent Moen, Joshua J Baltzell and Robert S White. View Insider Buying and Selling for Entellus Medical.

How do I buy Entellus Medical stock?

Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Entellus Medical's stock price today?

One share of Entellus Medical stock can currently be purchased for approximately $16.85.


MarketBeat Community Rating for Entellus Medical (NASDAQ ENTL)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Entellus Medical (NASDAQ:ENTL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $21.83 (29.57% upside)

Analysts' Ratings History for Entellus Medical (NASDAQ:ENTL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$21.00LowView Rating Details
5/22/2017Canaccord GenuitySet Price TargetHold$18.00LowView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
2/22/2017Bank of America CorporationDowngradeBuy -> Underperform$16.00N/AView Rating Details
2/22/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$25.00N/AView Rating Details
11/4/2016Deutsche Bank AGReiterated RatingBuy$25.00 -> $26.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Entellus Medical (NASDAQ:ENTL)
Earnings by Quarter for Entellus Medical (NASDAQ:ENTL)
Earnings History by Quarter for Entellus Medical (NASDAQ ENTL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/3/2017Q2 2017($0.34)($0.37)$21.87 million$22.10 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.44)($0.40)$19.61 million$19.11 millionViewListenView Earnings Details
2/21/2017Q4 2016($0.33)($0.39)$21.58 million$21.70 millionViewListenView Earnings Details
11/3/2016Q3($0.37)($0.50)$17.93 million$17.90 millionViewListenView Earnings Details
8/3/2016Q2($0.35)($0.27)$18.48 million$18.73 millionViewListenView Earnings Details
5/4/2016Q1($0.47)($0.37)$16.34 million$16.90 millionViewListenView Earnings Details
2/24/2016Q4($0.26)($0.27)$17.52 million$18.07 millionViewListenView Earnings Details
11/5/2015Q315($0.25)($0.32)$14.19 million$14.80 millionViewListenView Earnings Details
8/6/2015Q215($0.20)($0.15)$15.00 million$15.20 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Entellus Medical (NASDAQ:ENTL)
2017 EPS Consensus Estimate: ($1.35)
2018 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171($0.26)($0.26)($0.26)
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Entellus Medical (NASDAQ:ENTL)
Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 70.41%
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2017Stephen R. PaidoshVPSell25,000$17.54$438,500.00View SEC Filing  
5/8/2017Brent MoenCFOBuy6,100$12.21$74,481.00View SEC Filing  
5/8/2017Joshua J BaltzellDirectorBuy1,600$12.34$19,744.00View SEC Filing  
5/8/2017Robert S. WhiteInsiderBuy10,000$12.24$122,400.00View SEC Filing  
1/31/2017Life Sciences Fu InternationalMajor ShareholderSell533,077$17.00$9,062,309.00View SEC Filing  
1/13/2017Brian E FarleyDirectorSell14,019$20.14$282,342.66View SEC Filing  
1/13/2017Karen E. PetersonVPSell10,000$20.13$201,300.00View SEC Filing  
1/10/2017Brian E FarleyDirectorSell9,842$19.11$188,080.62View SEC Filing  
1/10/2017Karen E. PetersonVPSell9,840$19.11$188,042.40View SEC Filing  
1/4/2017Brian E FarleyDirectorSell20,158$18.74$377,760.92View SEC Filing  
1/4/2017Karen E PetersonVPSell10,160$18.74$190,398.40View SEC Filing  
12/6/2016Brian E FarleyDirectorSell15,000$18.57$278,550.00View SEC Filing  
11/23/2016Brian E FarleyDirectorSell5,000$19.00$95,000.00View SEC Filing  
11/18/2016Brian E FarleyDirectorSell10,000$18.30$183,000.00View SEC Filing  
10/13/2016Margaret A. BoianoVPSell11,103$20.01$222,171.03View SEC Filing  
10/5/2016Brian E FarleyDirectorSell30,000$22.26$667,800.00View SEC Filing  
9/8/2016James D SurekVPSell10,000$18.71$187,100.00View SEC Filing  
9/2/2016Brian E FarleyDirectorSell11,078$18.62$206,272.36View SEC Filing  
9/1/2016Brian E FarleyDirectorSell17,006$19.33$328,725.98View SEC Filing  
9/1/2016Kevin L. MensinkVPSell8,000$18.39$147,120.00View SEC Filing  
8/1/2016Kevin L MensinkVPSell8,100$17.63$142,803.00View SEC Filing  
7/18/2016Timothy B. PetrickVPSell3,000$18.15$54,450.00View SEC Filing  
2/11/2016Karen E PetersonInsiderSell5,000$16.00$80,000.00View SEC Filing  
2/4/2016Karen E PetersonInsiderSell10,000$17.00$170,000.00View SEC Filing  
9/17/2015Brian E. FarleyChairmanSell5,484$22.00$120,648.00View SEC Filing  
9/15/2015Brian E. FarleyChairmanSell27,619$22.18$612,589.42View SEC Filing  
9/14/2015Brian E. FarleyChairmanSell21,187$22.15$469,292.05View SEC Filing  
9/2/2015James D SurekVPSell15,000$21.27$319,050.00View SEC Filing  
8/31/2015James D. SurekVPSell5,000$22.29$111,450.00View SEC Filing  
2/3/2015Robert S WhiteCOOBuy5,882$17.00$99,994.00View SEC Filing  
2/3/2015Shawn MccormickDirectorBuy2,941$17.00$49,997.00View SEC Filing  
2/3/2015Woodlands Health Venture EssexMajor ShareholderBuy352,941$17.00$5,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Entellus Medical (NASDAQ:ENTL)
Latest Headlines for Entellus Medical (NASDAQ:ENTL)
Source:
DateHeadline
finance.yahoo.com logoEntellus Medical, Inc. – Value Analysis (NASDAQ:ENTL) : September 15, 2017
finance.yahoo.com - September 15 at 12:02 AM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) VP Stephen R. Paidosh Sells 25,000 Shares
www.americanbankingnews.com - September 14 at 11:16 PM
finance.yahoo.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bearish Manner : ENTL-US : September 13, 2017
finance.yahoo.com - September 13 at 7:40 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 9 at 6:26 AM
americanbankingnews.com logoContrasting Masimo Corporation (MASI) & Entellus Medical (ENTL)
www.americanbankingnews.com - August 29 at 4:22 PM
americanbankingnews.com logoPiper Jaffray Companies Reiterates Buy Rating for Entellus Medical, Inc. (ENTL)
www.americanbankingnews.com - August 22 at 4:28 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Lifted to Buy at BidaskClub
www.americanbankingnews.com - August 19 at 7:08 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 15 at 6:50 AM
finance.yahoo.com logoEntellus Medical Announces New Employee Inducement Option Grants
finance.yahoo.com - August 8 at 6:05 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Entellus Medical, Inc. (NASDAQ:ENTL) Will Post Quarterly Sales of $21.03 Million
www.americanbankingnews.com - August 8 at 7:34 AM
americanbankingnews.com logoCritical Contrast: Tactile Systems Technology (TCMD) versus Entellus Medical (NASDAQ:ENTL)
www.americanbankingnews.com - August 6 at 8:22 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - August 6 at 6:08 PM
seekingalpha.com logoEntellus Medical's (ENTL) CEO Bob White on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 5:29 PM
americanbankingnews.com logoEntellus Medical, Inc. (NASDAQ:ENTL) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 4 at 11:08 PM
finance.yahoo.com logoEdited Transcript of ENTL earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 6:33 PM
finance.yahoo.com logoEntellus reports 2Q loss
finance.yahoo.com - August 3 at 9:59 PM
finance.yahoo.com logoEntellus Medical Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:59 PM
americanbankingnews.com logoContrasting Tactile Systems Technology (TCMD) & Entellus Medical (ENTL)
www.americanbankingnews.com - August 3 at 2:38 PM
americanbankingnews.com logoEntellus Medical, Inc. (NASDAQ:ENTL) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - August 1 at 5:56 PM
americanbankingnews.com logoAnalyzing Entellus Medical (NASDAQ:ENTL) and Masimo Corporation (MASI)
www.americanbankingnews.com - July 31 at 9:33 AM
finance.yahoo.com logoEntellus Medical to Present at the Canaccord Genuity Annual Growth Conference
finance.yahoo.com - July 26 at 6:51 PM
americanbankingnews.com logoCritical Contrast: Entellus Medical (ENTL) vs. Penumbra (PEN)
www.americanbankingnews.com - July 22 at 2:15 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 21 at 7:40 AM
finance.yahoo.com logoEntellus Medical to Report Second Quarter 2017 Financial Results August 3, 2017
finance.yahoo.com - July 20 at 9:04 PM
americanbankingnews.com logoEntellus Medical, Inc. (NASDAQ:ENTL) Expected to Announce Quarterly Sales of $21.17 Million
www.americanbankingnews.com - July 19 at 1:28 PM
americanbankingnews.com logo Brokerages Expect Entellus Medical, Inc. (NASDAQ:ENTL) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - July 17 at 2:28 PM
americanbankingnews.com logoEntellus Medical (NASDAQ:ENTL) versus Penumbra (PEN) Head to Head Review
www.americanbankingnews.com - July 17 at 9:55 AM
americanbankingnews.com logoEntellus Medical Inc (NASDAQ:ENTL) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - July 16 at 11:06 AM
americanbankingnews.com logoReviewing Penumbra (PEN) & Entellus Medical (NASDAQ:ENTL)
www.americanbankingnews.com - July 13 at 6:40 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 12 at 7:56 AM
americanbankingnews.com logoEntellus Medical, Inc. (NASDAQ:ENTL) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - July 12 at 12:44 AM
americanbankingnews.com logoEntellus Medical, Inc. (NASDAQ:ENTL) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - July 8 at 7:08 PM
reuters.com logoBRIEF-Entellus Medical to acquire Spirox Inc
www.reuters.com - July 8 at 5:52 PM
streetinsider.com logoEntellus Medical (ENTL) to Acquire Spirox for $25M Cash, 3.4M Shares
www.streetinsider.com - July 8 at 5:52 PM
finance.yahoo.com logoEntellus Medical Announces Definitive Agreement to Acquire Spirox
finance.yahoo.com - July 8 at 10:30 AM
finance.yahoo.com logo[$$] Entellus Medical Agrees to Acquire KKR-Backed Spirox
finance.yahoo.com - July 8 at 10:30 AM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 5 at 6:50 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : July 3, 2017
finance.yahoo.com - July 3 at 6:09 PM
americanbankingnews.com logoEntellus Medical, Inc. (ENTL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 26 at 8:02 AM
americanbankingnews.com logo Analysts Expect Entellus Medical, Inc. (ENTL) Will Post Quarterly Sales of $21.17 Million
www.americanbankingnews.com - June 23 at 4:00 PM
americanbankingnews.com logoZacks: Analysts Anticipate Entellus Medical, Inc. (ENTL) to Announce -$0.34 EPS
www.americanbankingnews.com - June 21 at 12:08 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 5:59 PM
finance.yahoo.com logoEntellus Medical, Inc. :ENTL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 5:24 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM
finance.yahoo.com logoEntellus Medical to Present at the William Blair Growth Stock Conference
finance.yahoo.com - June 1 at 5:45 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 8:00 AM
americanbankingnews.com logo$21.17 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 28 at 9:54 AM
americanbankingnews.com logo-$0.34 Earnings Per Share Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 26 at 8:54 AM
americanbankingnews.com logoCanaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target
www.americanbankingnews.com - May 23 at 9:20 PM

Social

Chart

Entellus Medical (ENTL) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff